Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Apr 5;141(26):3184–3198. doi: 10.1182/blood.2022018619

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Figure 7. — Downregulation of TREM2 correlated with AML occurrence and inferior prognosis. (A) TREM2 profiles in peripheral blood mononuclear cells (PBMCs) from patients with AML (n = 20) and healthy individuals (n = 10; GSE33223). (B) TREM2 profiles in CD34⁺ blasts from patients with newly diagnosed AML (n = 3) and CD34⁺ cells from healthy donors (n = 3; GSE90062). (C) Overall survival in patients from the data given in GSE37642. Patient samples in the data sets of GSE37642 were from mononuclear cells (MNCs) isolated from BM aspirates from patients with AML. Log-rank analysis comparing different groups of patients (separated into tertiles) based on relative TREM2 expression (low TREM2 expression [n = 208] and high TREM2 expression [n = 209]). (D) The quantitative reverse transcription polymerase chain reaction analysis of TREM2 expression in bone marrow mononuclear cells (BMMCs) of patients with AML (n = 30) and CD34⁺ cells from healthy volunteers (n = 9). GAPDH was used as an internal reference gene. (E) Western blot analysis showing TREM2 expression in bulk BMMCs from healthy donors (n = 3) and patients with AML (n = 9) using GAPDH as an internal loading control. (F) Representative flow cytometry analysis of TREM2 expression in BMMCs from patients with AML (n = 18) and healthy individuals (n = 7). (G) Percentage of TREM2-positive cells in CD34⁺ cells from healthy donors (n = 7) and patients with AML (n = 18). (H) Mean fluorescence intensity (MFI) of TREM2 in CD34⁺ cells from healthy donors (n = 7) and patients with AML (n = 18). (I) Serum levels of IL-34 from patients with AML (n = 52) and healthy controls (n = 10). (J) Microarray data analysis of samples from patients with AML samples showing a significant positive correlation between the expressions of TREM2 and IL-34.